Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis.
The measurement errors associated with two techniques for brain atrophy assessment in multiple sclerosis (MS) were estimated. The measurement error of a semiautomated, nonnormalized technique with partial brain coverage was about twofold higher than that of a fully automated, normalized technique with full brain coverage (Structural Image Evaluation of Normalized Atrophy software [SIENA]). As shown by the analysis of data from a clinical trial of glatiramer acetate, the use of SIENA increases the study power to detect a treatment effect on brain volume changes in MS patients.
Sormani
M P
MP
Neuroimaging Research Unit, Department of Neurology, Scientific Institute and University Ospedale San Raffaele, Milan, Italy.
Rovaris
M
M
Valsasina
P
P
Wolinsky
J S
JS
Comi
G
G
Filippi
M
M
D001284:Atrophy / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D001921:Brain / Q000473:pathology*; D001927:Brain Diseases / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D004311:Double-Blind Method; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging / Q000379:methods* / Q000706:statistics & numerical data*; D009103:Multiple Sclerosis / Q000150:complications* / Q000188:drug therapy; D010455:Peptides / Q000627:therapeutic use; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013223:Statistics as Topic / Q000379:methods
D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate